Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can blood tests predict transplant complications?

NCT ID NCT07805746

Knowledge-focused Sponsor: Assistance Publique - Hôpitaux de Paris Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Sep 04, 2026 · Last updated Sep 04, 2026

Summary

This study looks at how levels of immune-signaling molecules called cytokines change in the blood just before and after a stem cell transplant. Researchers want to see if these patterns differ based on the patient's disease, such as myelofibrosis or acute leukemia, and the type of donor, such as a half-matched or fully matched donor. By comparing these groups, they hope to understand why some patients develop early inflammatory complications like graft-versus-host disease. The study involves collecting blood samples from adult patients at three time points around their transplant.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Blood sampling
What this could lead to
If successful, this could help doctors predict which transplant patients face a higher risk of early inflammatory complications, such as graft-versus-host disease, and tailor monitoring or treatment accordingly.
What could go wrong
This is an observational study with a small number of participants, so the findings may not apply broadly. Measuring cytokines in the blood may not fully capture the complex immune response after transplant.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 96 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Apr 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adult patient hospitalized for an allogeneic hematopoietic stem cell (HSC) transplantation for myelofibrosis, acute leukemia (AL), or myelodysplastic syndrome (MDS)

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Patients aged 18 years and older * With one of the following conditions: * Acute leukemia (AL) * Myelofibrosis (MF) * Myelodysplastic syndrome (MDS) * Indicated for allogeneic hematopoietic stem cell (HSC) transplantation from: * a haploidentical donor with post-transplant cyclophosphamide OR * a geno-identical donor, without post-transplant cyclophosphamide OR * a pheno-identical donor, without post-transplant cyclophosphamide Exclusion Criteria: * Lymphoma * Non-malignant disease * Patient's refusal to participate in this study * Patient's refusal to have their data recorded in the EBMT registry * Transplant from an unrelated donor 9/10 * Person under legal guardianship or curatorship, or unable to give informed consent * Person subject to judicial protective measures, or deprived of liberty by a judicial or administrative decision

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Acute leukemia are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

acute leukemia myelodysplastic syndrome Myelodysplastic Syndromes myelofibrosis primary myelofibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Acute leukemia Hematopoietic stem cell transplant (HSCT) Myelodysplastic syndrome Myelofibrosis

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  2. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

More trials for these conditions

Other studies related to the condition(s) this trial covers.